Oppenheimer Holdings, Inc. set a $21.00 price objective on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a research note released on Thursday, August 3rd. The firm currently has a buy rating on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ FY2021 earnings at $0.98 EPS.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research raised Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, June 14th. HC Wainwright assumed coverage on Vanda Pharmaceuticals in a research report on Friday, May 26th. They issued a buy rating and a $18.00 price objective for the company. CIBC reissued an outperform rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Jefferies Group LLC reissued a buy rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Finally, TheStreet raised Vanda Pharmaceuticals from a d+ rating to a c- rating in a research report on Friday, May 12th. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $21.33.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at 15.65 on Thursday. The company has a 50 day moving average of $16.16 and a 200-day moving average of $14.71. The company’s market cap is $702.03 million. Vanda Pharmaceuticals has a 52 week low of $11.58 and a 52 week high of $18.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same period in the prior year, the business earned $0.01 earnings per share. Vanda Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, equities research analysts expect that Vanda Pharmaceuticals will post ($0.52) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://transcriptdaily.com/2017/08/13/vanda-pharmaceuticals-inc-nasdaqvnda-given-a-21-00-price-target-at-oppenheimer-holdings-inc-updated.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its stake in shares of Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares during the period. FMR LLC raised its stake in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after buying an additional 521,669 shares during the last quarter. Nexthera Capital LP bought a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $7,171,000. Finally, Renaissance Technologies LLC boosted its position in shares of Vanda Pharmaceuticals by 65.3% in the first quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after buying an additional 370,900 shares during the period. Hedge funds and other institutional investors own 91.42% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.